While Mizuho maintains a Buy rating on MiMedx Group, indicating a positive outlook, the lowering of the price target from $14 to $12 suggests a potential decrease in the stock's value. This could lead to mixed investor sentiment, resulting in a neutral short-term impact on the stock.